NPJ

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus

Retrieved on: 
Monday, November 20, 2023
SIV, Food, Antigen, IND, Antibody, Arenavirus, FDA, The Mark of Gideon, Simian immunodeficiency virus, Vaccination, NPJ, Animal, HIV, Vaccine, LCMV, Gilead Sciences, Viral load

HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial.

Key Points: 
  • HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial.
  • The analyses published were conducted with a simian immunodeficiency virus (SIV) model, commonly used in a preclinical setting as a surrogate to HIV.
  • One vector is based on lymphocytic choriomeningitis virus (LCMV) as its arenaviral backbone; another vector is based on Pichinde virus (PICV).
  • HB-500 is one of two separate development programs in HOOKIPA’s collaboration and license agreement with Gilead.

Isolation of Circulating Tumor Cells with TellDx Platform Reveals Potential Mechanism of Resistance to Immune Checkpoint Blockade in Melanoma

Retrieved on: 
Thursday, March 16, 2023
Cancer, Chinese, PD, CR, DRS, Crownsville Hospital Center, CD8, KEAP1, Biomarker, Doctor of Pharmacy, CTC, ICB, Patient, Toxicity, Metastasis, NRF2, Melanoma, Massachusetts General Hospital, NPJ, Harvard Medical School, RNA, Doctor of Philosophy, DOI, Neoplasm, HIV disease progression rates, Vaccine, Medical imaging

BEVERLY, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- TellBio, Inc., a development stage biotechnology company focused on revolutionizing the detection of cancer through its unique and proprietary circulating tumor cell (CTC) technology, the TellDx CTC System, announces publication of data from the scientific founders that reveal downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade (ICB). The paper, titled “Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade,” was published on March 02, 2023, in NPJ Precision Oncology (DOI 10.1038/s41698-023-00362-3).

Key Points: 
  • The paper, titled “Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade,” was published on March 02, 2023, in NPJ Precision Oncology (DOI 10.1038/s41698-023-00362-3 ).
  • While ICB has significantly improved clinical outcomes in melanoma, a subset of patients do not respond or develop resistance over time.
  • “These exciting data demonstrate that isolation of CTCs from melanoma patients with the TellDx platform and subsequent single cell RNA sequencing can reveal pathways of response and resistance to ICB.
  • Overall, these data provide valuable insights into the mechanisms behind melanoma resistance to immune checkpoint blockade therapy and highlight the potential of monitoring CTCs to improve outcomes of patients with cancer.

Lumen Bioscience Details 2022 Company and Facilities Growth, New Funding, and Clinical Pipeline Progress

Retrieved on: 
Thursday, January 5, 2023
Bill & Melinda Gates Foundation, Lumen, ESG, GMP, Vaccine, NPJ, Tropical disease, Drug development, Research, ETEC, Bill, Clostridioides difficile infection, R, Growth, Malaria, CGMP, FDA, COVID-19, NIH, Recurrence, Nature Biotechnology, BARDA, Dietary supplement, Financial services, Pharmaceutical industry, IND

"In 2022 we experienced strong growth across all facets of our company and operations, positioning Lumen for significant events in the coming year," said Brian Finrow, co-founder and CEO of Lumen Bio.

Key Points: 
  • "In 2022 we experienced strong growth across all facets of our company and operations, positioning Lumen for significant events in the coming year," said Brian Finrow, co-founder and CEO of Lumen Bio.
  • Some aspects of 2022 progress include:
    Commercial Pipeline — An accelerating pipeline of clinical stage programs targeting prevalent, unmet needs backed by blockbuster commercial opportunities.
  • LMN-201 for prevention of C. difficile infection – LMN-201 is the world's first rationally engineered, complex biologic cocktail to enter human clinical trials.
  • LMN-301 for Covid-19 – In 2022, Lumen Bio's Covid-19 funding consortium expanded to include BARDA and the Bill & Melinda Gates Foundation .

3STEP Sports Acquires North Pacific Juniors Volleyball Club

Retrieved on: 
Monday, December 5, 2022
General Sports, Sports, Teens, Children, Other Sports, Consumer, Other Consumer, Volleyball, Athlete, Sport, Pacific Northwest, NPJ, Volleyball, Policy, Chiropractic, Massage, Sports equipment, Nightclub, Toy

3STEP Sports , the nations largest and most impactful youth sports club and event operator, has acquired North Pacific Juniors Volleyball Club (NPJ) , adding another foundational volleyball organization in the verticals expansion into the Pacific Northwest.

Key Points: 
  • 3STEP Sports , the nations largest and most impactful youth sports club and event operator, has acquired North Pacific Juniors Volleyball Club (NPJ) , adding another foundational volleyball organization in the verticals expansion into the Pacific Northwest.
  • In Salem, the club operates out of the NPJ Sports Complex, which features 38,000 square feet, six courts and in-house chiropractic, massage and nutrition centers.
  • There is a robust in-house recruiting program and the club takes pride in the fact that everyone who has sought to play college volleyball has done so.
  • In Bend, the club operates five beach volleyball courts and runs programming and tournaments.

GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 9, 2022
Capsid, Pfizer, IND, Travel, Risk, NIH, Lip, Exercise, Delta, Virus, Company, Public health, Security (finance), Immunization, Patent, Thomas Jefferson University, City, MVA, SPX, Immunotherapy, University of North Carolina at Greensboro, U.S. Securities and Exchange Commission, Cancer, Emory University, Vaccination, Research, Stanford University, Patient, CEO, HIV, COVID-19, Investigational New Drug, Mutation, Nasdaq, Webcast, EST, Tongue, GeoVax, HNSCC, Cell, Biotechnology, FDA, GLOBE, Head, NPJ, Severe acute respiratory syndrome coronavirus 2, Primate, US Foods, Safety, Infection, SUDV, University, MPX, Pharmaceutical industry, Vaccine, Monkeypox, Omicron, Smallpox

ATLANTA, GA, Nov. 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial results for the third quarter ended September 30, 2022.

Key Points: 
  • ATLANTA, GA, Nov. 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial results for the third quarter ended September 30, 2022.
  • GeoVaxs management will host a live conference call and webcast at 4:30 p.m. EST on Wednesday, November 9, 2022, to provide a general business update and discuss financial results.
  • During the November 9th Corporate Update call, GeoVax will provide a progress report on study expansion developments.
  • Management will host a conference call, scheduled to begin at 4:30 p.m. EST today, November 9, 2022, to review financial results and provide an update on corporate developments.

The Access to Advanced Health Institute Develops Longer Lasting and Broadly Protective SARS-CoV-2 RNA Vaccine Candidate that is Stable at Room Temperature

Retrieved on: 
Wednesday, November 2, 2022
COVID-19, Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, RNA, MD, Face, SaRNA, COVID, Science, Partnership, Clinical trial, Cancer, Research, Infectious Disease Research Institute, Degenerative disease, COVID-19, Disease, Immune system, Immunodeficiency, Transport, Government, Fungus, NPJ, Technology, NLC, Vaccine, Temperature, Access, Severe acute respiratory syndrome coronavirus 2, Parasitism, Solution, ImmunityBio

Today, the Access to Advanced Health Institute (AAHI) announced results from a study of their new RNA vaccine against COVID-19.

Key Points: 
  • Today, the Access to Advanced Health Institute (AAHI) announced results from a study of their new RNA vaccine against COVID-19.
  • AAHIs RNA vaccines can easily be freeze-dried for long-term room temperature or refrigerated stability (10+ months).
  • The SARS-CoV-2 RNA vaccine candidate, AAHI-SC2, is currently being evaluated in liquid form in a first-in-human Phase 1 / 2 clinical trial sponsored by ImmunityBio in South Africa ( NCT05370040 ).
  • The improved temperature stability of AAHI-SC2 enables more equitable access to COVID RNA vaccines, especially in rural and remote communities where resources are limited.

GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate Against Sudan Ebolavirus Showing 100% Protection With a Single Immunization

Retrieved on: 
Thursday, July 28, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Vaccine, Death, Form, List of Nature Research journals, FC, GLOBE, SUDV, Zika virus, Food, Human, NPJ, Doctor of Philosophy, CEO, SEC, Research, Immunodeficiency, Patent, Virus-like particle, Immune system, Malaria, COVID-19, Head, Cancer, GeoVax, Biotechnology, Infection, FDA, Company, Patient, Nasdaq, VP40, MVA, Membrane protein, Primate, Guinea pig, Animal, Risk

GeoVaxs vaccine, MVA-VLP-SUDV, combines the advantages of the immunogenicity of a live attenuated vaccine vector with the authentic conformation of virus-like particles (VLPs).

Key Points: 
  • GeoVaxs vaccine, MVA-VLP-SUDV, combines the advantages of the immunogenicity of a live attenuated vaccine vector with the authentic conformation of virus-like particles (VLPs).
  • The vaccine expresses minimal components to generate self-assembling VLPs in the vaccinee: the envelope glycoprotein GP and the matrix protein VP40.
  • These data demonstrate single dose protection and potency of the MVA-VLP platform for use in emergency situations to contain outbreaks.
  • Previously, our vaccine against the Zaire ebolavirus demonstrated 100% protection, single-dose protection in a non-human primate model.

Hummingbird Diagnostics Publishes Study of miRisk as a Predictor of Immunotherapy Efficacy in Advanced-Stage NSCLC

Retrieved on: 
Thursday, June 23, 2022
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Doctor of Philosophy, RNA, Reading, NPJ, Journal, Technology, Association, Survival, OS, Precision medicine, Large-cell lung carcinoma, Disease, Physician, Mirna, MD, MicroRNA, Health, Quality of life, Biomarker, IO, Precision, ICT, University Hospital Heidelberg, Patient, NSCLC, PD-L1, Immunotherapy, Medical imaging

The score could identify high-risk patients who might benefit from treatment with ICT, as opposed to IO, and support treatment decisions as a blood-based complementary diagnostics.

Key Points: 
  • The score could identify high-risk patients who might benefit from treatment with ICT, as opposed to IO, and support treatment decisions as a blood-based complementary diagnostics.
  • Patients with advanced, non-oncogene-driven, non-small-cell lung cancer (NSCLC) with high PD-L1 expression are eligible for treatment with immunotherapy.
  • These samples were subject to small RNA sequencing and used to train and validate a 5-microRNA model to predict OS (miRisk).
  • A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy.